Granted Patent B2

US 12,331,335 · App. 18/338,255 · Granted Jun 17, 2025

Inventor: Scott W. Rowlinson (Austin, TX)

Assignee: Immedica Pharma AB

C12N9/78C07K1/18C07K1/36C12N1/06C12Y305/03001

Abstract

Claims (50)

1. A method for producing purified recombinant cobalt-substituted human Arginase, wherein the recombinant human Arginase (rhARG) comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 1, the method comprising:

a) in a bioreactor, culturing E. coli cells that produce rhARG;

b) lysing the E. coli cells;

c) removing cell debris from the lysate;

d) loading the cell lysate on a cation exchange column;

e) eluting the rhARG with a high salt solution;

f) incubating the eluted rhARG with a cobalt salt to form cobalt-substituted rhARG (Co-rhARG);

g) applying said Co-rhARG to an anion exchange column and collecting the flow-through;

h) applying the flow-through onto a third chromatography column; and

i) eluting the Co-rhARG from the third chromatography column with a high salt solution.

2. The method of claim 1 , wherein up to 60 grams of rhARG is loaded onto the cation exchange column per liter of cation exchange resin.

3. The method of claim 1 , wherein eluting the rhARG from the cation exchange column uses a high salt solution of up to 0.5 M salt concentration.

4. The method of claim 1 , wherein eluting the rhARG from the cation exchange column uses a high salt solution of 0.1 M salt concentration.

5. The method of claim 1 , wherein eluting the rhARG from the cation exchange column uses a gradient of 0.0 to 0.5 M salt concentration.

6. The method of claim 1 , wherein eluting the rhARG from the cation exchange column uses a gradient of 0.0 to 0.2M salt concentration.

7. The method of claim 1 , wherein the cobalt salt comprises a Co 2+ salt.

8. The method of claim 1 , wherein the cobalt salt comprises CoCl 2 .

9. The method of claim 1 , wherein the third chromatography column comprises a multimodal chromatography (MMC) column.

10. The method of claim 1 , further comprising reacting the rhARG or Co-rhARG with a PEGylation reactant to provide a PEGylated protein.

11. The method of claim 10 , wherein the PEGylated protein comprises one or more of PEGylated amino acid residues at K16, K32, K38, K40, K47, K67, K74, K82, L87, K88, K152, K154, K171, K222, K223, K312 and K321.

12. The method of claim 11 , wherein the PEGylated protein comprises one or more of 15% to 60% of K16, 35% to 80% of K32, 20% to 85% of K38, 10% to 60% of K40, 10% to 60% of K47, 40% to v 90% of K67, 30% to 95% of K74, 30% to v 98% of K82, 15% to 65% of K87, 25% to 70% of K88, 25% to 85% of K152, 15% to 65% of K154, 20% to 75% of K171, 0% to 30% of K222, 0% to 35% of K223, 0% to 45% of K312, and 0% to 45% of K321 is PEGylated.

13. The method of claim 10 , wherein the PEGylated protein comprises PEGylated amino acid residues at least at K16, K32, K38, K40, K47, K67, K74, K82, L87, K88, K152, K154, K171, K312 and K321.

14. The method of claim 10 , wherein the PEGylated protein does not have PEGylated amino acid residues at K3, K149, K190, K195, K29, K265 and K283.

15. A method for producing purified PEGylated recombinant cobalt-substituted human Arginase, wherein the recombinant human Arginase (rhARG) comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 1, the method comprising:

a) in a bioreactor, culturing E. coli that produce rhARG;

b) lysing the E. coli cells;

c) removing cell debris from the lysate;

d) loading the cell lysate on a cation exchange column;

e) eluting the rhARG with a high salt solution;

f) incubating the eluted rhARG with 10 mM CoCl 2 to form cobalt-substituted rhARG (Co-rhARG);

g) applying the Co-rhARG to an anion column and collecting the flow-through;

h) applying the flow-through onto a multimodal chromatography (MMC) column;

i) eluting the Co-rhARG from the MMC column with a high salt solution;

j) adding a molar excess of methoxy PEG succinimidyl carboxymethyl ester;

k) removing excess PEG.

16. A method for producing purified recombinant cobalt-substituted human Arginase, wherein the recombinant human Arginase (rhARG) comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 1, the method comprising:

a) in a bioreactor, culturing E. coli cells that produce rhARG at 36° C. to 38° C., and pH of between 7.0 and 7.4, with agitation and aeration;

i) adjusting the temperature of the bioreactor to 29° C.;

ii) inducing E. coli cells to produce for rhARG;

iii) culturing the E. coli cells for 18 hours;

iv) harvesting the E. coli cells by centrifugation;

b) lysing the E. coli cells by high pressure homogenization in 25 mM HEPES at a pH of between 7.2 to 7.6, and at or below 15° C.;

c) removing cell debris from the lysate by centrifugation at or below 15° C., then filtering the lysate with a 0.8 micron filter then filtering with a 0.5 micron filter;

d) loading the cell lysate on a cation exchange column then washing the column with 25 mM HEPES, pH 7.2-7.6;

e) eluting the rhARG at room temperature with a high salt solution comprising 25 mM HEPES, 0.1M NaCl, pH 7.2-7.6;

f) incubating the eluted rhARG with 10 mM CoCl 2 at room temperature for 2 to 8 hours to form cobalt-substituted rhARG (Co-rhARG);

i) exchanging Co-rhARG into 50 mM Tris, pH 8.1-8.5;

g) applying the Co-rhARG to an anion exchange column and collecting the flow-through;

h) applying the flow-through onto a Capto multimodal chromatography (MMC) column;

i) eluting the Co-rhARG from the MMC column with a high salt solution comprising 50 mM Tris, 250 mM NaCl, pH 8.1-8.5.

Assignments (2)

Continuity (3)

References Cited (278)